SS Innovations International (NASDAQ: SSII) has reported significant growth in the utilization of its SSi Mantra surgical robotic system, with cumulative procedures reaching 14,103 as of September 8, 2026. This represents a 79% increase from 7,885 procedures at the end of 2025. The installed base of SSi Mantra systems grew 42% to 238 units, up from 168 at year-end 2025. These figures underscore the company's expanding presence in the global surgical robotics market and its potential to challenge established competitors by offering a more affordable and accessible solution.
The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the platform. The system has been used for more than 170 types of surgical procedures, demonstrating its versatility. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the company's ability to penetrate new markets and adapt its technology to diverse healthcare environments.
In addition to its general surgery applications, SS Innovations has emphasized the system's use in pediatric and telesurgery. As of August 31, 2026, the company reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries, including a telesurgery performed over a distance of more than 13,600 miles between Colombia and India. This feat demonstrates the potential of the SSi Mantra to enable remote surgical care, which could be particularly impactful in underserved or geographically isolated regions. Furthermore, in August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, showcasing the system's efficiency and reliability in high-volume settings.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. The company also believes it can obtain European Union CE marking certification by year-end 2026. These regulatory milestones are critical for the company's expansion into major markets and could significantly accelerate adoption if achieved. The FDA clearance would allow SS Innovations to compete directly in the United States, the world's largest market for surgical robotics, while CE marking would open access to the European Union.
For a more detailed report, visit https://ibn.fm/DJILj. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The company's product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
